![](https://investorshub.advfn.com/uicon/413007.png?cb=1673699831)
Monday, August 24, 2020 10:48:32 AM
When I saw this I thought the same thing. I am not sure why I didn't pickup on this earlier (probaby because it has been very quiet since 2016 on the Terumo front in Europe). I think there is more to this partnership than meets the eye.
Just a refresher, back in 2016 CTSO inked a distribution partnership with Terumo for six European countries: France and the Nordic countries of Denmark, Finland, Iceland, Norway, and Sweden, for cardiac surgery applications. There was some overlap with Fresenius who had distribution rights for acute care in most of these same territories before they CTSO negotiated getting those back in exchange for Mexico and South Korea. I think most would admit that it's been pretty quiet on the Terumo European front in terms of news but keep in mind they only had rights to distribute for cardiac surgery and in those territories there are 'only' about 70,000 heart surgeries performed each year vs worldwide there are over close to 2 million.
Baxter and Terumo are chief competitors in the medical device space. Terumo having about $5B in revenue compared to Baxter with $11M in annual revenue. In terms of revenue and size of the company (employees) Baxter is twice as big. Baxter obtained FDA EUA for Oxiris which is their own filter. Baxter also has an exclusive distribution agreement with Spectral for the U.S. and Canda for Toraymyxin which complements their own filter by removing endoxins.
In my opinion, both CTSO and Terumo came together on this to establish this partnership on COVID to fend off further expansion of Baxter's products into more U.S. hospitals, and a prelude to a much bigger partnership with a trial and potential exclusive rights for the removal of ticagrelor and other NOAC's. Remember that some of the risk has been removed for a strategic partner for the removal of NOAC's, whether that be Terumo or someone else, since the FDA has already granted the device breakthrough status. I am also sure Terumo Cardiovascular (this division) has been closely following what's been going on with the removal of ticagrelor and the recent breakthrough designation. As stated in the press release, Cytosorb fits nicely with Terumos other products specifically their CAPIOX ECMO machine and their Advanced Perfusion System heart lung machine. Terumo would also give CTSO access to Japan which is a significant market.
Recent CTSO News
- CytoSorbents Secures $20 Million Credit Facility • GlobeNewswire Inc. • 07/02/2024 11:00:00 AM
- CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan • GlobeNewswire Inc. • 06/24/2024 11:00:00 AM
- CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union • GlobeNewswire Inc. • 06/13/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:31:20 PM
- CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting • GlobeNewswire Inc. • 06/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:35:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:23:00 PM
- CytoSorbents Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/09/2024 08:17:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:14:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:00:30 PM
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 04/26/2024 11:00:00 AM
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation • GlobeNewswire Inc. • 12/28/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:35:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:33:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:55 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM